Editas Medicine, Inc.
- Open
- 3.10
- Day high
- 3.14
- Day low
- 3.02
- Prev close
- 3.16
- Volume
- 2.1M
- Mkt cap
- $470M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 4.5
- P/S
- 10.0
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$60K over the last 3 months (0 open-market buys, 5 sales)
- 🏛Institutions accumulating (13F)
Editas Medicine, Inc. (EDIT) is a Healthcare company listed on NASDAQ. The stock is up 25% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 5 sales (SEC Form 4).
Editas Medicine, Inc. (EDIT) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
EDIT earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 5, 2026 | $-0.27 | $-0.15 | +44.5% | $12M | +317.7% |
| May 5, 2026 | $-0.30 | $-0.26 | +13.3% | $3M | -55.6% |
| Mar 9, 2026 | $-0.23 | $-0.06 | +74.2% | $25M | +724.7% |
| Mar 5, 2025 | $-0.39 | $-0.55 | -41.0% | $31M | +4680.0% |
| Feb 28, 2024 | $-0.52 | $-0.23 | +55.8% | $60M | +664.3% |
| Nov 3, 2023 | $-0.64 | $-0.55 | +14.1% | $5M | +56.0% |
| Aug 2, 2023 | $-0.76 | $-0.56 | +26.3% | $3M | -30.8% |
| May 5, 2023 | $-0.79 | $-0.71 | +10.1% | $10M | +220.2% |
| Feb 22, 2023 | $-0.84 | $-0.88 | -4.8% | $7M | +78.7% |
| Nov 2, 2022 | $-0.87 | $-0.81 | +6.9% | — | — |
| Aug 3, 2022 | $-0.84 | $-0.78 | +7.1% | $6M | +48.3% |
| May 4, 2022 | $-0.81 | $-0.74 | +8.6% | $7M | +75.8% |
EDIT insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 7, 2026 | Ellinor Patrick Thomas IIdirector | Grant | 103,400 | $2.90 |
| Aug 5, 2026 | Parison Amyofficer: SVP, Chief Financial Officer | Sell | 678 | $2.58 |
| Jul 29, 2026 | Burkly Lindaofficer: EVP, CHIEF SCIENTIFIC OFFICER | Sell | 4,928 | $2.67 |
| Jun 22, 2026 | Levy Elliott M.director | Grant | 51,700 | $2.55 |
| Jun 22, 2026 | Hirsch Andrewdirector | Grant | 51,700 | $2.55 |
| Jun 22, 2026 | Hopfield Jessicadirector | Grant | 51,700 | $2.55 |
| Jun 22, 2026 | Scadden Daviddirector | Grant | 51,700 | $2.55 |
| Jun 22, 2026 | Connaughton Bernadettedirector | Grant | 51,700 | $2.55 |
| Jun 5, 2026 | Burkly Lindaofficer: EVP, CHIEF SCIENTIFIC OFFICER | Sell | 731 | $2.70 |
| Jun 5, 2026 | Parison Amyofficer: SVP, Chief Financial Officer | Sell | 464 | $2.70 |
| Jun 5, 2026 | O'Neill Gilmore Neildirector, officer: CEO | Sell | 15,380 | $2.70 |
| Mar 16, 2026 | Burkly Lindaofficer: EVP, CHIEF SCIENTIFIC OFFICER | Grant | 292,856 | $2.54 |
| Mar 16, 2026 | O'Neill Gilmore Neildirector, officer: CEO | Grant | 1,015,200 | $2.54 |
| Mar 16, 2026 | Parison Amyofficer: SVP, Chief Financial Officer | Grant | 292,856 | $2.54 |
| Mar 4, 2026 | O'Neill Gilmore Neildirector, officer: CEO | Sell | 5,394 | $2.02 |
Source: EDIT SEC Form 4 filings, latest Aug 7, 2026. For informational purposes only — not investment advice.
See the full EDIT insider & 13F page →Editas Medicine, Inc. company profile
Overview
Editas Medicine, Inc. (NASDAQ:EDIT) is a clinical-stage biotechnology company founded in 2013 and based in Cambridge, Massachusetts. The company was originally incorporated as Gengine, Inc. before changing its name in November 2013. Editas went public in February 2016 and has since established itself as a pioneer in the genome editing field, focusing on developing transformative genomic medicines using CRISPR technology to treat serious diseases. The company operates primarily in the gene therapy and cell therapy sectors, with programs targeting inherited diseases, blood disorders, and cancer.
Business
Editas Medicine operates in the rapidly evolving field of genome editing, which involves making precise changes to DNA sequences to correct genetic defects or enhance cellular function. The company's core technology platform is based on CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), a revolutionary gene editing system that acts like molecular scissors to cut DNA at specific locations, allowing scientists to add, remove, or alter specific DNA sequences. The company's business is organized around several key therapeutic areas. EDIT-301 (reni-cel) represents their most advanced program, targeting sickle cell disease and beta-thalassemia through ex-vivo gene editing of hematopoietic stem cells. This approach involves removing a patient's blood stem cells, editing them in the laboratory to produce fetal hemoglobin (which can substitute for defective adult hemoglobin), and then reinfusing the edited cells back into the patient. In the ocular disease space, Editas develops EDIT-101 for Leber Congenital Amaurosis 10, a rare inherited form of childhood blindness, and EDIT-102 for Usher Syndrome 2A, which causes both vision and hearing loss. These programs use in-vivo gene editing, where the CRISPR system is delivered directly to the eye to correct genetic mutations. The company also has an emerging in-vivo editing pipeline focused on functional upregulation of gene expression, targeting rare and orphan diseases by enhancing the activity of existing genes rather than correcting defective ones. Additionally, Editas is developing gene-edited cell therapies for cancer, including Natural Killer (NK) cells and T cell therapies designed to better recognize and attack tumor cells. Revenue is currently minimal and primarily derived from collaboration agreements and licensing deals, with the company generating approximately $32 million in 2024 revenue, largely from partnership agreements with companies like Bristol-Myers Squibb and previous deals with Vertex Pharmaceuticals.
Revenue model
Editas Medicine operates on a typical biotech business model focused on developing proprietary therapies through clinical trials with the ultimate goal of commercializing approved treatments. The company currently generates revenue through several channels: licensing agreements with pharmaceutical partners, research collaboration fees, and milestone payments from strategic partnerships. The company's primary revenue source has been its collaboration agreements. For example, a significant portion of 2023's $78 million revenue came from a licensing agreement with Vertex Pharmaceuticals. The company also has ongoing collaborations with Bristol-Myers Squibb and has extended these partnerships, generating steady but modest collaboration revenue. Once Editas successfully brings therapies to market, the business model will shift toward product sales revenue from commercialized gene therapies. These treatments, particularly for rare diseases, typically command premium pricing due to their specialized nature and limited patient populations. The company is also exploring partnership arrangements for commercialization outside the United States, which would generate royalty income and reduce the capital requirements for global market entry. Several factors significantly impact the company's financial margins and prospects. Regulatory approval timelines directly affect when revenue can begin flowing from product sales, while manufacturing costs for complex gene therapies remain substantial. The company's AsCas12a enzyme technology and targeting of the HBG1/2 promoter region represent potential competitive advantages that could support premium pricing. However, competition from other gene editing companies like those developing similar sickle cell therapies could pressure future pricing power. Clinical trial success rates pose the most significant risk to the business model, as failure in late-stage trials can eliminate years of investment. Additionally, the company's focus on rare diseases, while offering less competition, also limits the total addressable market size. The company targets initial markets of approximately $400-500 million, which provides meaningful revenue potential but requires successful execution across multiple indications to achieve substantial scale.
Competitive moat
Editas Medicine's competitive moat is primarily built around its proprietary CRISPR technology platform and intellectual property portfolio, though this moat faces significant challenges in the rapidly evolving gene editing landscape. The company's use of the AsCas12a enzyme provides some differentiation from competitors using more common Cas9 systems, potentially offering advantages in editing efficiency and reduced off-target effects. The company's specific targeting approach for sickle cell disease, focusing on the HBG1/2 promoter region to upregulate fetal hemoglobin production, represents a potentially differentiated mechanism compared to other gene editing approaches. This technical differentiation, combined with clinical data showing normalization of total hemoglobin levels and elimination of vaso-occlusive events, could provide a competitive advantage if these results prove superior to competing therapies. However, Editas faces substantial competitive pressure that weakens its moat considerably. Vertex Pharmaceuticals and CRISPR Therapeutics have already achieved regulatory approval for their gene-edited sickle cell therapy (Casgevy), giving them a significant first-mover advantage. Bluebird Bio and other companies are also developing competing therapies for similar indications, creating a crowded competitive landscape. The company's intellectual property position, while valuable, operates in a field where patent disputes are common and where the foundational CRISPR patents are held by multiple parties. Additionally, the rapid pace of technological advancement in gene editing means that today's cutting-edge approaches may become obsoleted by newer, more efficient technologies. The high barriers to entry in gene therapy development, including regulatory expertise, manufacturing capabilities, and clinical trial execution, do provide some protection. However, these same barriers also limit the company's ability to rapidly scale and defend market position against well-funded competitors with greater resources.
Risks & safety
Editas Medicine presents a moderate margin of safety typical of clinical-stage biotech companies, with adequate liquidity but significant execution risks. • Cash position: $139 million in cash and short-term investments as of Q1 2025, providing runway into 2026 based on current burn rates • Burn rate: Approximately $48 million quarterly free cash flow burn, indicating roughly 3 quarters of remaining runway at current spending levels • Debt levels: Relatively low debt-to-equity ratio of 0.50, indicating manageable leverage • Current ratio: Strong liquidity position with current ratio of 3.08, well above the 1.0 threshold for near-term solvency • Valuation metrics: Trading at significant discount with P/B ratio of 1.54 and negative earnings due to development stage • Market cap: Approximately $160 million market capitalization represents substantial discount to net tangible assets • Graham net-net: Ratio of 0.24 indicates trading below liquidation value, suggesting potential asset-based value • Clinical risk: Primary risk stems from clinical trial outcomes, particularly for lead program reni-cel • Competitive pressure: Approved competing therapies reduce market opportunity and pricing power • Regulatory timeline: Uncertain path to BLA submission creates execution risk for primary value driver
Recent development
Over the past few years, Editas Medicine has undergone significant strategic repositioning to focus its resources on the most promising opportunities. In 2022, the company implemented a major strategic refocusing initiative, reducing headcount by approximately 20% and divesting non-core assets including the iNK Cell Franchise to Shoreline Biosciences. The company also terminated its AAV-based inherited retinal disease program to concentrate resources on in-vivo genome editing approaches. The company's reni-cel program has emerged as the primary value driver, with substantial clinical progress across both the RUBY trial for sickle cell disease and the EdiTHAL trial for beta-thalassemia. Clinical data presented at the European Hematology Association meeting in 2024 demonstrated that all patients in the RUBY trial remained free from vaso-occlusive events with robust anemia correction and high fetal hemoglobin levels. The company completed enrollment of adult cohorts and initiated adolescent cohorts, representing a significant expansion of the addressable patient population. Editas has also pivoted toward developing a broader in-vivo editing pipeline focused on functional upregulation using indel technology rather than traditional gene correction approaches. This strategy targets rare and orphan diseases initially, with plans to establish preclinical proof-of-concept by focusing on hematopoietic stem cells and liver as initial target tissues. The company aims to be first or best-in-class in selected indications with market sizes of approximately $400-500 million. The company has strengthened its business development activities, extending collaborations with Bristol-Myers Squibb and actively exploring intellectual property monetization opportunities. Management has indicated openness to partnerships for reni-cel commercialization outside the United States, recognizing the capital requirements for global market development while maintaining focus on bringing therapies to patients efficiently.
EDIT company profile · for informational purposes only — not investment advice.
Track EDIT with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free